Objectives: The aim of the study was to analyse the susceptibility of unique and non-duplicate aerobic and anaerobic isolates from surgical patients to a novel des-F(6)-quinolone (garenoxacin) and other selected antimicrobial agents.
Introduction
Since the introduction of ciprofloxacin in the late 1980s, the fluoroquinolones have been viewed as a potent group of anti-infectives for serious Gram-negative infections. However, prior to the development of trovafloxacin the fluoroquinolones were considered as having limited utility as monotherapy for surgical infections. Serious intra-abdominal infections resulting from Fax: +1-414-454-0152; E-mail: edmiston@mcw.edu surgical complications or perforation of the gastrointestinal tract often involve multiple bacterial strains, including Gram-negative aerobic and facultative bacilli, anaerobic bacilli and Gram-positive cocci. [1] [2] [3] Effective monotherapy for potentially serious abdominal and deep tissue infections requires an agent that exhibits broadspectrum activity against both aerobic and anaerobic bacteria, demonstrating adequate distribution into targeted tissues. 4, 5 To achieve broad-spectrum coverage against polymicrobial bacterial infections, multidrug regimens have commonly been used. The fluoroquinolones represent a potent group of anti-infectives for serious Gram-negative infections. 6 These agents exhibit a broadspectrum of activity and a favourable pharmacokinetic profile that make them attractive for use in a variety of bacterial infections. [6] [7] [8] However, despite their demonstrated efficacy in the treatment of serious bacterial infections such as complicated intra-abdominal and diabetic foot infections, their use has been limited by adverse events or lack of adequate anaerobic coverage. 3, 6, 7, 9 Garenoxacin is a novel des-F-(6)-quinolone that is being investigated for a variety of bacterial infections, including intraabdominal and diabetic foot infections. While historically, quinolone activity against selected staphylococcal isolates has been poor, it has been suggested that garenoxacin may exhibit good to excellent in vitro activity against a broad spectrum of clinically important bacteria including selected strains of methicillinresistant Staphylococcus aureus (MRSA) as well as Gram-positive/ Gram-negative aerobes and anaerobic microorganisms. [10] [11] [12] [13] [14] In addition to its broad-spectrum bactericidal properties, the pharmacokinetic and safety profile of garenoxacin may make it an appropriate monotherapeutic option for serious polymicrobial surgical infections and other treatment-resistant infections. 15 This comparative in vitro study was conducted to determine the antimicrobial activity of garenoxacin against aerobic and anaerobic microbial isolates recovered in culture from selected surgical tissues and device-related infections. This study was approved by the institutional IRB.
Materials and methods
Eleven-hundred and eighty-five unique and non-duplicate aerobic (531) and anaerobic (654) microbial isolates were obtained over a 3 year period (1999-2002) from five surgical services: trauma, general, vascular, cardiothoracic and otolaryngology. The microbial isolates representative of multiple loci of infection were recovered from intra-operative cultures, including intra-abdominal, skin and skin structure, pulmonary abscess, rhinosinusitis or biomedical device-related infections (catheter-related blood stream infections, ventilator-associated pneumonia and explanted prosthetic devices). NCCLS-recommended reference broth and agar dilution methods were used for respective aerobic and anaerobic susceptibility testing. 16, 17 Microbroth and agar dilution plates were prepared the day of testing and incubated at 35 C for 24 h (aerobes) and 48 h (anaerobes), respectively. Gram-positive and Gram-negative aerobic/facultative isolates were tested in Mueller-Hinton broth. Anaerobic strains were tested on brucella blood agar plates supplemented with 5 mg haemin, 1 mg vitamin K 1 per mL and 5% lysed sheep blood. The agar-dilution plates were inoculated (10 5 cfu/spot) using a 32-prong Steers replicator device. Antimicrobial standard powders were reconstituted according to instructions obtained from the manufacturers, serially diluted, and added to appropriate media for testing: garenoxacin (Bristol-Myers Squibb, Princeton, NJ, USA); ciprofloxacin and moxifloxacin ( The Gram-negative in vitro activity of garenoxacin was similar to the activity of ciprofloxacin, moxifloxacin and levofloxacin ( Table 1 ). The activity of garenoxacin against strains of E. coli from intra-abdominal locus was similar to ciprofloxacin, levofloxacin and moxifloxacin (-one dilution). However, the MIC 90 values for garenoxacin and moxifloxacin against Klebsiella pneumoniae were three dilutions higher than the MIC 90 for ciprofloxacin and levofloxacin Overall, garenoxacin demonstrated similar in vitro activity against anaerobic bacteria compared with moxifloxacin, with the exception of selected strains including Bacteroides vulgatus and 
Discussion
Infections that involve the diabetic limb, abdominal/pelvic vaults and head/neck often comprise a mixed microbial flora. Common microbial populations associated with intra-abdominal infections include enterococci, Klebsiella species, Bacteroides species, Enterobacter species, staphylococci, E. coli and P. aeruginosa.
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In the case of head/neck infection, many of the bacterial isolates express potent b-lactamase activity requiring use of a b-lactam/ inhibitor combination for effective treatment. 18 While agents such as ciprofloxacin, levofloxacin and gatifloxacin have been used in the treatment of severe polymicrobial infections, such as diabetic foot infections, they must be used in combination with an antianaerobic drug for optimal antimicrobial coverage. In addition, many surgical infections occur in sites where there is significant disruption of tissue plains and vascular supply. 3, 4 The quinolones have been used successfully in a broad range of surgical infections, especially in regions of poor vascular perfusion, such as in diabetic foot, intra-abdominal abscesses or the obstructed biliary tree. 3, 5, 7 The present in vitro data suggest that garenoxacin would be an effective agent for the treatment of infection in surgical patients involving either a mono or polymicrobial flora, such as those organisms associated with biomedical device-associated infection, intra-abdominal infection, soft tissue or diabetic foot infections, pulmonary abscess, nosocomial pneumonia (ventilator-associated pneumonia), or selected head and neck infections. In the present study, garenoxacin demonstrated good to excellent in vitro activity against a broad group of Gram-positive organisms. This in vitro activity encompassed many of the strains that are commonly responsible for difficult to treat healthcare-associated infections. For example, garenoxacin was active against penicillin non-susceptible S. pneumoniae, with an MIC 90 four times lower than that of moxifloxacin and 66 times lower than that of levofloxacin and ciprofloxacin. While garenoxacin was active against selected strains of MRSA, including quinolone-susceptible and resistant S. aureus (MIC 90 = 0.5 and 4.0 mg/L, respectively), a cautionary note is indicated since the quinolones have, in general, demonstrated limited or poor clinical utility against these serious In vitro activity of garenoxacin in surgical patients Clostridium species: C. bifermentans (2), C. butyricum (1), C. cadaveris (3), C. difficile (4), C. hastiforme (1), C. histolyticum (2), C. innocuum (7), C. ramosum (7), C. sporogenes (1), C. subterminale (6), C. tertium (2), C. tyrobutyricum (1 Although garenoxacin demonstrated in vitro activity against most of these organisms, the MIC 90 values observed for ciprofloxacin and levofloxacin indicated that these agents exhibited greater in vitro activity against many Gram-negative isolates, including E. coli, K. pneumoniae and Proteus mirabilis. None of the antibiotics tested was highly active against the Pseudomonas species, with the exception of piperacillin/tazobactam. Garenoxacin, imipenem and piperacillin/tazobactam demonstrated good to excellent activity against most Gram-positive and Gram-negative anaerobic bacteria. Approx. 90% of B. fragilis group surgical isolates were inhibited by a garenoxacin concentration £1.0 mg/L. A recent study has also noted that garenoxacin exhibited excellent in vitro activity against members of the B. fragilis group. 12 However, other investigators have suggested that the MIC 90 range of garenoxacin for all members of the B. fragilis group was between 4.0 and 32.0 mg/L. 19, 20 Resistance of anaerobic bacteria to trovafloxacin and other quinolones has been suggested to be due to mutations in the gyrase (gyrA) and topoisomerase IV (parC) genes with or without involvement of an efflux pump. 21 The clinical impact of these findings is currently unknown.
In healthy subjects, once-daily dosing with garenoxacin results in plasma trough levels of >1.0 mg/L at a dose of 400 mg. 15 A recent study using a microdialysis technique for in situ analysis of subcutaneous tissue concentrations of moxifloxacin in patients with soft tissue infection found that tissue concentrations mimicked plasma levels. 22 While published microdialysis garenoxacin data in patients are currently lacking, the present in vitro susceptibility findings (MIC 90 values £1.0 mg/L for 82.4% and 84.5% of aerobic and anaerobic surgical isolates, respectively) indicate that if tissue levels of garenoxacin are found to mimic published plasma values then that would suggest a possible therapeutic utility in the treatment of selected surgical infections. Such broad-spectrum activity, if validated in clinical trials would make garenoxacin an appropriate choice for the treatment of severe mono or polymicrobial surgical infections.
